[
  {
    "ts": "2025-12-31T12:32:00+00:00",
    "headline": "Can BMY's Growth Portfolio Drive Top-Line Expansion in 2026?",
    "summary": "Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.",
    "url": "https://finance.yahoo.com/news/bmys-growth-portfolio-drive-top-123200885.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "050132de-e323-38e2-ac8c-e70e56843344",
      "content": {
        "id": "050132de-e323-38e2-ac8c-e70e56843344",
        "contentType": "STORY",
        "title": "Can BMY's Growth Portfolio Drive Top-Line Expansion in 2026?",
        "description": "",
        "summary": "Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.",
        "pubDate": "2025-12-31T12:32:00Z",
        "displayTime": "2025-12-31T12:32:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bmys-growth-portfolio-drive-top-123200885.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bmys-growth-portfolio-drive-top-123200885.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T14:34:42+00:00",
    "headline": "Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs",
    "summary": "List prices to rise an average of 4% despite federal pressure to curb costs.",
    "url": "https://finance.yahoo.com/news/pfizer-gsk-lead-u-drugmakers-143442942.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "60f9e371-cf5c-34d8-8971-8c8928c120be",
      "content": {
        "id": "60f9e371-cf5c-34d8-8971-8c8928c120be",
        "contentType": "STORY",
        "title": "Pfizer, GSK Lead U.S. Drugmakers Planning 2026 Price Hikes on 350 Drugs",
        "description": "",
        "summary": "List prices to rise an average of 4% despite federal pressure to curb costs.",
        "pubDate": "2025-12-31T14:34:42Z",
        "displayTime": "2025-12-31T14:34:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4",
          "originalWidth": 500,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vu.kxzmN7yCA.wz8Cs.cHg--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4.cf.webp",
              "width": 500,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Brb0J12XOUXl4lathAg3vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-gsk-lead-u-drugmakers-143442942.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-gsk-lead-u-drugmakers-143442942.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T14:00:04+00:00",
    "headline": "Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?",
    "summary": "Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finance.yahoo.com/news/trending-stock-bristol-myers-squibb-140004878.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "12902aac-8789-3c2a-a986-33cd90e73d74",
      "content": {
        "id": "12902aac-8789-3c2a-a986-33cd90e73d74",
        "contentType": "STORY",
        "title": "Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?",
        "description": "",
        "summary": "Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
        "pubDate": "2025-12-31T14:00:04Z",
        "displayTime": "2025-12-31T14:00:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y.YEouD16bNWn6FshAyysg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sqqoypFHTaqTKxA9xCsU7A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/trending-stock-bristol-myers-squibb-140004878.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/trending-stock-bristol-myers-squibb-140004878.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T17:05:00+00:00",
    "headline": "2 Dividend Stocks to Scoop Up Without Hesitation Right Now",
    "summary": "These stocks can be great sources of portfolio growth in the years ahead.",
    "url": "https://www.fool.com/investing/2025/12/31/2-dividend-stocks-to-scoop-up-right-now/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "76c40779-a8cc-3562-bb1d-f72eff1552c4",
      "content": {
        "id": "76c40779-a8cc-3562-bb1d-f72eff1552c4",
        "contentType": "STORY",
        "title": "2 Dividend Stocks to Scoop Up Without Hesitation Right Now",
        "description": "",
        "summary": "These stocks can be great sources of portfolio growth in the years ahead.",
        "pubDate": "2025-12-31T17:05:00Z",
        "displayTime": "2025-12-31T17:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/cc07906ed92fb4020def8fe343f85442",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Excited investor pointing at purple wall. ",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UOxhdvUvpSSZrtNX.lWx7w--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/cc07906ed92fb4020def8fe343f85442.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QFvvxFATl_aeYpK3SMPRVg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/cc07906ed92fb4020def8fe343f85442.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/31/2-dividend-stocks-to-scoop-up-right-now/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-dividend-stocks-scoop-without-170500329.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VICI"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-31T19:08:24+00:00",
    "headline": "Drugmakers hike US prices on 350 medicines despite pressure from Trump",
    "summary": "<body><p>STORY: :: Bristol Myers Squibb&nbsp;</p><p>:: File</p><p>Drugmakers plan to raise U.S. prices on at least 350 branded medications in 2026, including vaccines and blockbuster cancer treatment Ibrance.</p><p>:: CVS</p><p>That's according to data provided exclusively to Reuters by healthcare research firm 3 Axis Advisors.</p><p>The hikes come even as&nbsp;the Trump administration is pressuring drugmakers for cuts.</p><p>:: CVS</p><p>The number of price increases is up from the same point last year while the median price hike of four percent is in line with 2025.</p><p>The increases do not reflect any rebates to pharmacy benefit managers and other discounts.</p><p>:: Boehringer Ingelheim</p><p>Drugmakers also plan to cut the list prices on around nine drugs including diabetes treatment Jardiance, which is dropping 40%.</p><p>It is among the 10 drugs for which the U.S. government negotiated a lower price for the Medicare program for people aged 65 and older in 2026.</p><p>:: Pfizer</p><p>A health policy researcher tells Reuters these deals are being announced as transformative when, in fact, they really just nibble around the margins in terms of what is really driving high prices for prescription drugs in the U.S.</p><p>:: CVS</p><p>U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations.</p><p>Pfizer announced the most list price hikes, on around 80 different drugs including cancer drug Ibrance, and its COVID vaccine, which is going up 15%.</p><p>:: Pfizer</p><p>:: File</p><p>Pfizer said in a statement it had adjusted the average list price of its innovative medicines and vaccines for 2026 below the overall rate of inflation.</p><p>:: CVS</p><p>More price hikes and cuts can be expected in early January, which is historically the biggest month for drugmakers to raise prices.</p></body>",
    "url": "https://finance.yahoo.com/video/drugmakers-hike-us-prices-350-190824459.html",
    "source": "Reuters Videos",
    "provider": "yfinance",
    "raw": {
      "id": "4e512a37-8fb5-3392-960d-d2a0c17cb629",
      "content": {
        "id": "4e512a37-8fb5-3392-960d-d2a0c17cb629",
        "contentType": "VIDEO",
        "title": "Drugmakers hike US prices on 350 medicines despite pressure from Trump",
        "description": "<title><body><p>STORY: :: Bristol Myers Squibb </p><p>:: File</p><p>Drugmakers plan to raise U.S. prices on at least 350 branded medications in 2026, including vaccines and blockbuster cancer treatment Ibrance.</p><p>:: CVS</p><p>That's according to data provided exclusively to Reuters by healthcare research firm 3 Axis Advisors.</p><p>The hikes come even as the Trump administration is pressuring drugmakers for cuts.</p><p>:: CVS</p><p>The number of price increases is up from the same point last year while the median price hike of four percent is in line with 2025.</p><p>The increases do not reflect any rebates to pharmacy benefit managers and other discounts.</p><p>:: Boehringer Ingelheim</p><p>Drugmakers also plan to cut the list prices on around nine drugs including diabetes treatment Jardiance, which is dropping 40%.</p><p>It is among the 10 drugs for which the U.S. government negotiated a lower price for the Medicare program for people aged 65 and older in 2026.</p><p>:: Pfizer</p><p>A health policy researcher tells Reuters these deals are being announced as transformative when, in fact, they really just nibble around the margins in terms of what is really driving high prices for prescription drugs in the U.S.</p><p>:: CVS</p><p>U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations.</p><p>Pfizer announced the most list price hikes, on around 80 different drugs including cancer drug Ibrance, and its COVID vaccine, which is going up 15%.</p><p>:: Pfizer</p><p>:: File</p><p>Pfizer said in a statement it had adjusted the average list price of its innovative medicines and vaccines for 2026 below the overall rate of inflation.</p><p>:: CVS</p><p>More price hikes and cuts can be expected in early January, which is historically the biggest month for drugmakers to raise prices.</p></body></title>",
        "summary": "<body><p>STORY: :: Bristol Myers Squibb&nbsp;</p><p>:: File</p><p>Drugmakers plan to raise U.S. prices on at least 350 branded medications in 2026, including vaccines and blockbuster cancer treatment Ibrance.</p><p>:: CVS</p><p>That's according to data provided exclusively to Reuters by healthcare research firm 3 Axis Advisors.</p><p>The hikes come even as&nbsp;the Trump administration is pressuring drugmakers for cuts.</p><p>:: CVS</p><p>The number of price increases is up from the same point last year while the median price hike of four percent is in line with 2025.</p><p>The increases do not reflect any rebates to pharmacy benefit managers and other discounts.</p><p>:: Boehringer Ingelheim</p><p>Drugmakers also plan to cut the list prices on around nine drugs including diabetes treatment Jardiance, which is dropping 40%.</p><p>It is among the 10 drugs for which the U.S. government negotiated a lower price for the Medicare program for people aged 65 and older in 2026.</p><p>:: Pfizer</p><p>A health policy researcher tells Reuters these deals are being announced as transformative when, in fact, they really just nibble around the margins in terms of what is really driving high prices for prescription drugs in the U.S.</p><p>:: CVS</p><p>U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations.</p><p>Pfizer announced the most list price hikes, on around 80 different drugs including cancer drug Ibrance, and its COVID vaccine, which is going up 15%.</p><p>:: Pfizer</p><p>:: File</p><p>Pfizer said in a statement it had adjusted the average list price of its innovative medicines and vaccines for 2026 below the overall rate of inflation.</p><p>:: CVS</p><p>More price hikes and cuts can be expected in early January, which is historically the biggest month for drugmakers to raise prices.</p></body>",
        "pubDate": "2025-12-31T19:08:24Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/uu/api/res/1.2/ZCCRAgQw1H4VhTmnL7SSQA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/e21a6b31-ae49-498d-95b6-6a3f82b510e7/main/1280x720/54s810ms/match/image.jpg",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4mDLafeQQaddaMhF3eT6lQ--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/e21a6b31-ae49-498d-95b6-6a3f82b510e7/main/1280x720/54s810ms/match/image.jpg.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zoZEDfwosxLKq9swoWWhzQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/e21a6b31-ae49-498d-95b6-6a3f82b510e7/main/1280x720/54s810ms/match/image.jpg.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters Videos",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/drugmakers-hike-us-prices-350-190824459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/drugmakers-hike-us-prices-350-190824459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]